TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in
patients with platinum refractory or resistant ovarian cancer.